InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,436.00
(
-0.73%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
72.06
(
0.50%
)
Bitcoin
64,403.10
(
-1.87%
)
Post# of 253252
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

go seek

Send PM Follow Ignore
Followers 21
Posts 4840
Boards Moderated 0
Alias Born 06/24/2006

go seek

Member Level

Re: julescat post# 85557

Thursday, 10/29/2009 6:56:21 PM

Thursday, October 29, 2009 6:56:21 PM

Post# of 253252
a knee-jerk market reaction on the NVS decision not to license...
will not be surprised to see IDIX move back above today's close of @2.50 in short order.

...So we get another company w/ strong anti-viral development experience to opt in. Any guesses on who Idenix may be talking to?

Gilead
Abbott
Glaxo Smith Kline
Schering Plough
Bristol Myers Squibb
Merck
Pfizer
Roche

Some of the above have significant efforts in the HCV space and 'may' fit very well with Idenix / nuc IDX184.

http://www.hcvdrugs.com/
#msg-42917735

The creation of a thousand forests is in one acorn.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up